“Mesenchymal stem cell-derived exosomes (MSC-exosomes) in hematology: From mechanisms to clinical breakthroughs”

📖 Top 20% JournalJun 11, 2025Cellular immunology

Stem cell-derived exosomes in blood diseases: from how they work to medical advances

AI simplified

Abstract

MSC-derived exosomes (MSC-EXOs) may enhance therapeutic strategies in treating hematological diseases.

MSC-EXOs are nanosized extracellular vesicles that carry proteins, lipids, and nucleic acids.
They share benefits with mesenchymal stem cells, such as immune regulation and tissue repair.
MSC-EXOs have shown potential to suppress tumor growth and improve conventional therapy efficacy.
They can specifically target cancer cells and induce apoptosis.
Challenges include standardization of isolation methods and understanding their mechanisms of action.
Continued research is necessary to ensure the safety and efficacy of MSC-EXO-based therapies.

AI simplified

Mesenchymal stem cells (MSCs) offer promising therapy because they regulate the immune system and help repair tissues. However, challenges such as low cell survival rates, immune rejection, and ethical concerns related to their clinical use have limited their widespread application. To overcome these limitations, MSC-derived exosomes (MSC-EXOs) have emerged as an innovative and promising cell-free therapeutic strategy. MSC-EXOs are nanosized extracellular vesicles released by MSCs that carry a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids. They share many benefits with MSCs, including immune regulation, anti-inflammatory effects, and tissue repair. MSC-EXOs demonstrate therapeutic potential by modulating the tumor microenvironment, suppressing tumor growth, and enhancing the efficacy of conventional therapies. They can specifically target cells, deliver therapeutic agents, and induce apoptosis in cancer cells. Additionally, MSC-EXOs can modulate the immune response, promote hematopoietic recovery, and alleviate treatment-related side effects. While MSC-EXOs present a promising therapeutic approach, several challenges remain, including the standardization of isolation and characterization methods, understanding their mechanisms of action, and ensuring both safety and efficacy. Despite these challenges, the future of MSC-EXO-based therapies in hematology is promising. Continued research efforts are essential to unravel the intricate biology of exosomes, identify novel biomarkers, and develop innovative therapeutic strategies. By harnessing the power of MSC-EXOs, we can revolutionize the treatment of hematological diseases and improve patient outcomes.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Abstract

Full Text

Related papers